C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

• Main Authors: Adam J. Nelson (Author), Rishi Puri (Author), Danielle M. Brennan (Author), Todd J. Anderson (Author), Leslie Cho (Author), Christie M. Ballantyne (Author), John JP. Kastelein (Author), Wolfgang Koenig (Author), Helina Kassahun (Author), Ransi M. Somaratne (Author), Scott M. Wasserman (Author), Steven E. Nissen (Author), Stephen J. Nicholls (Author)
• Formato: Livro
• Publicado em: Elsevier, 2020-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective: On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors produce additional LDL-C lowering, r...